At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZLAB Zai Lab Ltd
Market Closed 12-12 16:00:00 EST
17.77
-0.05
-0.28%
盘后17.79
+0.02+0.10%
18:32 EST
High18.67Low17.72Vol852.80K
Open18.28D1 Closing17.82Amplitude5.33%
Mkt Cap1.98BTradable Cap1.94BTotal Shares111.27M
T/O15.36MT/O Rate0.78%Tradable Shares109.37M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Ends Week Flat
MT Newswires Live  ·  12-12 23:44
Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Ends Week Flat
How Investors Are Reacting To Zai Lab (ZLAB) Advancing ZL-1503 And Securing Key NRDL Renewals
Simply Wall St.  ·  12-10
How Investors Are Reacting To Zai Lab (ZLAB) Advancing ZL-1503 And Securing Key NRDL Renewals
Zai Lab Begins Phase 1/1b Study of Atopic Dermatitis Therapy
MT Newswires Live  ·  12-08
Zai Lab Begins Phase 1/1b Study of Atopic Dermatitis Therapy
Zai Lab Says China Renews 3 Medicines in 2025 National Reimbursement Drug List
MT Newswires Live  ·  12-08
Zai Lab Says China Renews 3 Medicines in 2025 National Reimbursement Drug List
Zai Lab (09688) Grants Stock Options and Restricted Share Units
Stock News  ·  12-03
Zai Lab (09688) Grants Stock Options and Restricted Share Units
A Look at Zai Lab (NasdaqGM:ZLAB) Valuation Following Q3 2025 Results and Pipeline Progress
Simply Wall St.  ·  12-02
A Look at Zai Lab (NasdaqGM:ZLAB) Valuation Following Q3 2025 Results and Pipeline Progress
What Zai Lab (ZLAB)'s Q3 Results and Reaffirmed 2025 Guidance Mean for Shareholders
Simply Wall St.  ·  12-01
What Zai Lab (ZLAB)'s Q3 Results and Reaffirmed 2025 Guidance Mean for Shareholders
Zai Lab (09688) Issues 2 Million Shares Under Equity Incentive Plans
Stock News  ·  11-19
Zai Lab (09688) Issues 2 Million Shares Under Equity Incentive Plans
Zai Lab Ltd Announces Share Options and Restricted Share Units Grants
TIPRANKS  ·  11-11
Zai Lab Ltd Announces Share Options and Restricted Share Units Grants
Zai Lab (09688) Grants Stock Options and Restricted Share Units
Stock News  ·  11-11
Zai Lab (09688) Grants Stock Options and Restricted Share Units
Zai Lab Ltd (1ZLB) Gets a Buy from UBS
TIPRANKS  ·  11-11
Zai Lab Ltd (1ZLB) Gets a Buy from UBS
Stock Track | Zai Lab Plummets 5.05% Pre-Market Amid Broader Decline in Hong Kong's Innovative Drug Sector
Stock Track  ·  11-07
Stock Track | Zai Lab Plummets 5.05% Pre-Market Amid Broader Decline in Hong Kong's Innovative Drug Sector
Hong Kong Stock Connect Innovative Drug Sector Declines in Afternoon Session, Zai Lab Plunges 10%, 520880 Drops 2% Below 10-Day Moving Average, Intraday Premium Surges
Deep News  ·  11-07
Hong Kong Stock Connect Innovative Drug Sector Declines in Afternoon Session, Zai Lab Plunges 10%, 520880 Drops 2% Below 10-Day Moving Average, Intraday Premium Surges
Zai Lab (09688) Reports 14% YoY Revenue Growth in Q3, Totaling $116.1 Million
Stock News  ·  11-06
Zai Lab (09688) Reports 14% YoY Revenue Growth in Q3, Totaling $116.1 Million
Zai Lab Q3 Loss Narrows, Revenue Rises; 2025 Revenue Outlook Revised
MT Newswires Live  ·  11-06
Zai Lab Q3 Loss Narrows, Revenue Rises; 2025 Revenue Outlook Revised
Stock Track | Zai Lab Plunges 6.45% in Pre-market as Q3 Earnings Miss Estimates
Stock Track  ·  11-06
Stock Track | Zai Lab Plunges 6.45% in Pre-market as Q3 Earnings Miss Estimates
Earnings Flash (ZLAB) Zai Lab Posts Q3 Revenue $116.1M, vs. FactSet Est of $141.7M
MT Newswires Live  ·  11-06
Earnings Flash (ZLAB) Zai Lab Posts Q3 Revenue $116.1M, vs. FactSet Est of $141.7M
Zai Lab Q3 EPADS $(0.33) Misses $(0.05) Estimate, Sales $116.095M Miss $136.703M Estimate
Benzinga  ·  11-06
Zai Lab Q3 EPADS $(0.33) Misses $(0.05) Estimate, Sales $116.095M Miss $136.703M Estimate
Zai Lab (09688) Provides Update on Amgen's Bemarituzumab Phase 1b/3 FORTITUDE-102 Clinical Trial
Stock News  ·  11-05
Zai Lab (09688) Provides Update on Amgen's Bemarituzumab Phase 1b/3 FORTITUDE-102 Clinical Trial
Zai Lab (NasdaqGM:ZLAB): Evaluating Valuation Following Promising Trial Results and Phase 3 Progress
Simply Wall St.  ·  11-02
Zai Lab (NasdaqGM:ZLAB): Evaluating Valuation Following Promising Trial Results and Phase 3 Progress

Introduction

Company Name.
Zai Lab Ltd
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Issue price:
--